Wednesday, October 7, 2015

GSK profit drops in first quarter

GlaxoSmithKline said Wednesday that first-quarter, after-tax profit dropped about 13 percent compared to the first quarter of 2011.

GSK profit drops in first quarter


GlaxoSmithKline said Wednesday that first-quarter, after-tax profit dropped about 13 percent compared to the first quarter of 2011.

The global pharmaceutical manufacturer is based in London, but has operations in Center City and in Philadelphia suburbs.

The decline can be attributed at least partially to the absence of the one-time payment in 2011 for GSK's interest in Quest, the U.S. laboratory diagnostic company.

GSK had after-tax profit of $2.55 billion in the first quarter in 2011, but that figure dropped to $2.24 billion in 2012.

Sales in the United States grew nine percent for GSK products, while Europe had a six percent decline.

"We remain mindful of the challenges we face given the current global political and economic environment, particularly in relation to pricing on our more established products," chief executive officer Sir Andrew Witty said in a statement.

"However, we also continue to see attractive growth opportunities across our businesses and we intend to continue to invest behind them to strengthen the breadth and mix of the Group and its future growth prospects. 2012 is a very important year for pipeline delivery and so far the performance has been encouraging. This year we have received a significant amount of positive data for five Phase III assets for the treatment of HIV, cancer, diabetes and asthma."

Inquirer Staff Writer
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at or 215-854-4506.

David Sell Inquirer Staff Writer
Also on
letter icon Newsletter